Medication-Use Evaluation of Recombinant Human Factor VIIa [PDF]
Global Journal on Quality and Safety in Healthcare, 2020 Introduction: Medication-use evaluation (MUE) is a performance improvement method used to achieve optimal patient outcomes. The recombinant human factor VIIa (rFVIIa) (NovoSeven) is an expensive agent approved by the U.S.
Abrar Al-Subhi +2 more
doaj +2 more sources
Factor X and combined factor VIIa/factor X augment coagulation potential in a plasma model of antithrombin-reduced hemophilia [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Plasma-derived (pd) factor (F)VIIa/FX products are available for the hemostatic management of people with hemophilia with inhibitors in Japan. We have previously reported that FX alone augments emicizumab-driven hemostasis.
Shigeharu Oh +4 more
doaj +2 more sources
Tissue Factor–Factor VIIa Signaling [PDF]
Arteriosclerosis, Thrombosis, and Vascular Biology, 2005 How does tissue factor (TF), whose principle role is to support clotting factor VIIa (FVIIa) in triggering the coagulation cascade, affect various pathophysiological processes? One of the answers is that TF interaction with FVIIa not only initiates clotting but also induces cell signaling via activation of G-protein–coupled protease activated receptors
Vijaya Lella, Usha R Pendurthi
exaly +3 more sources
Membrane-bound model of the ternary complex between factor VIIa/tissue factor and factor X [PDF]
Blood Advances: Formation of the extrinsic complex (EC) on cell surfaces is the event that triggers the coagulation cascade. Tissue factor (TF) and factor VIIa (FVIIa) form the EC together with FX on phosphatidylserine-containing membranes, leading to FX activation by
Melanie P. Muller +5 more
doaj +2 more sources
Limited factor VIIa surface localization requirement of the factor VIIa–induced overall thrombin generation in platelet‐rich hemophilia A plasma [PDF]
Research and Practice in Thrombosis and Haemostasis, 2019 Background Thrombin generation assay (TGA) and thrombelastography (TEG) are increasingly employed, global, in vitro methods for assessment of the procoagulant potential of plasma/blood and possibly ideally suited tools to monitor, for example, therapy ...
Egon Persson, Mette Winther
doaj +2 more sources
In vitro characterization of CT‐001—a short‐acting factor VIIa with enhanced prohemostatic activity [PDF]
Research and Practice in Thrombosis and Haemostasis, 2021 Background Traumatic injury and the associated acute bleeding are leading causes of death in people aged 1 to 44 years. Acute bleeding in pathological and surgical settings also represents a significant burden to the society.
Derek S. Sim +5 more
doaj +2 more sources
Prostasin and hepatocyte growth factor B in factor VIIa generation: Serine protease knockdowns in zebrafish [PDF]
Research and Practice in Thrombosis and Haemostasis, 2020 Background Blood clotting in humans is initiated by the binding of tissue factor to activated coagulation factor VII (FVIIa) in the plasma. Previous studies have reported that hepsin and factor VII (FVII)‐activating protease are responsible for ...
Gauri Khandekar +2 more
doaj +2 more sources
Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue [PDF]
Blood Advances, 2019 : Vatreptacog alfa (VA), a recombinant activated human factor VII (rFVIIa) variant with 3 amino acid substitutions, was developed to provide increased procoagulant activity in hemophilia patients with inhibitors to factor VIII or factor IX.
Wojciech Jankowski +12 more
doaj +2 more sources
Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center [PDF]
Clinical and Applied Thrombosis/HemostasisBackground Eptacog alfa and eptacog beta are recombinant factor VIIa (rFVIIa) agents approved for use in hemophilia A or B with inhibitors. Our institution converted from eptacog alfa to eptacog beta as the preferred rFVIIa product. The objective of this
Alyssa R. George PharmD, BCPS, CACP +6 more
doaj +2 more sources
Tissue factor residues that putatively interact with membrane phospholipids. [PDF]
PLoS ONE, 2014 Blood clotting is initiated by the two-subunit enzyme consisting of the plasma protease, factor VIIa (the catalytic subunit), bound to the integral membrane protein, tissue factor (the regulatory subunit).
Ke Ke, Jian Yuan, James H Morrissey
doaj +1 more source